Wealthspire Advisors (New York)’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$843K Sell
10,531
-4,807
-31% -$396K 0.01% 444
2025
Q4
$1.31M Buy
15,338
+3,842
+33% +$315K 0.01% 372
2025
Q3
$894K Buy
11,496
+2,940
+34% +$230K ﹤0.01% 414
2025
Q2
$669K Sell
8,556
-1,823
-18% -$136K ﹤0.01% 470
2025
Q1
$752K Buy
10,379
+630
+6% +$45.1K ﹤0.01% 442
2024
Q4
$722K Sell
9,749
-1,820
-16% -$127K 0.01% 427
2024
Q3
$763K Buy
11,569
+1,001
+9% +$72.7K 0.01% 418
2024
Q2
$976K Sell
10,568
-1,349
-11% -$119K 0.01% 315
2024
Q1
$1.14M Sell
11,917
-895
-7% -$75.2K 0.02% 295
2023
Q4
$977K Buy
12,812
+393
+3% +$27.3K 0.01% 314
2023
Q3
$860K Buy
+12,419
New +$998K 0.01% 299
2023
Q1
Sell
-3,124
Closed -$233K 553
2022
Q4
$233K Buy
+3,124
New +$241K ﹤0.01% 510
2022
Q1
Sell
-2,404
Closed -$311K 476
2021
Q4
$311K Buy
2,404
+300
+14% +$35K 0.01% 408
2021
Q3
$238K Buy
+2,104
New +$240K ﹤0.01% 506
2021
Q2
Sell
-8,507
Closed -$712K 475
2021
Q1
$712K Buy
8,507
+1,179
+16% +$99.7K 0.02% 325
2020
Q4
$669K Buy
7,328
+2,207
+43% +$183K 0.02% 259
2020
Q3
$409K Buy
5,121
+232
+5% +$18.1K 0.02% 197
2020
Q2
$338K Sell
4,889
-5,824
-54% -$414K 0.02% 190
2020
Q1
$674K Buy
+10,713
New +$773K 0.03% 254
2019
Q1
Sell
-501
Closed -$26K 290
2018
Q4
$26K Buy
+501
New +$25.3K ﹤0.01% 284

Other funds holding EW

Wealthspire Advisors (New York)'s EW Position: Q1 2026 in Review

Wealthspire Advisors (New York) reduced its Edwards Lifesciences (EW) stake by 31% in Q1 2026, selling an estimated $396K and leaving 10,531 shares worth $843K. The position accounts for 0.01% of the portfolio, ranked #444.

Wealthspire Advisors (New York) first reported a position in EW in Q4 2018 and has held it in 20 quarters since. The position peaked at $1.31M in Q4 2025. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Wealthspire Advisors (New York) held 10,531 shares of Edwards Lifesciences worth $843K as of Q1 2026.
  • Wealthspire Advisors (New York) sold 4,807 Edwards Lifesciences shares in Q1 2026, an estimated $396K.
  • Edwards Lifesciences made up 0.01% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #444 holding.
  • Wealthspire Advisors (New York) first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 20 quarters since.
  • Wealthspire Advisors (New York)'s Edwards Lifesciences position peaked at $1.31M in Q4 2025.
  • 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.